Patents by Inventor Richard Green

Richard Green has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Patent number: 11513059
    Abstract: A contamination sensor for a gas turbine engine is disclosed herein. The contamination sensor is made of a selected composition of material and includes a base alloy, an alloy for improving oxide formation, and at least one element from the transition metal group. The composition of the contamination sensor can be adjusted to react with specific contaminants at specific temperature ranges.
    Type: Grant
    Filed: April 6, 2020
    Date of Patent: November 29, 2022
    Assignee: Solar Turbines Incorporated
    Inventors: Noel Glaenzer, Richard Green, Prabhakar Mohan, Christopher Meyer
  • Publication number: 20220349123
    Abstract: A process for bleaching trichome fibers individualized from a trichome source, such as a leaf and/or a stem, is disclosed. The process of bleaching degrades trichome associated protein. Further, the bleaching processes improves the color of the trichomes.
    Type: Application
    Filed: July 19, 2022
    Publication date: November 3, 2022
    Inventors: Phillip Richard Green, Raul Victorino Nunes, Nicholas William Geary, Khosrow Parviz Mohammadi
  • Patent number: 11466069
    Abstract: The present invention provides novels method of targeting delivery of a compound to hypoxic cells, for example treatment of diseases and disorders associated with hypoxia, comprising administration of a construct comprising a targeting carrier peptide and a compound for delivery to a hypoxic cell. The invention also provides novel methods for the treatment of diseases or disorders of the eye by administration of a novel construct, a nucleic acid encoding a novel construct, and/or a nucleic acid vector comprising a nucleic acid encoding a novel construct. The invention further provides novel constructs, nucleic acids encoding such constructs, and/or nucleic acid vectors comprising nucleic acids encoding such constructs.
    Type: Grant
    Filed: April 30, 2018
    Date of Patent: October 11, 2022
    Assignee: AUCKLAND UNISERVICES LIMITED
    Inventors: Colin Richard Green, Frazer Paul Coutinho, Ilva Dana Rupenthal
  • Publication number: 20220288163
    Abstract: The inventions relate to the use of hemichannel blockers to modulate cytokine levels in a subject, including the angiogenic cytokine, VEGF, and their production, secretion and/or release, and to the use of hemichannel blockers to reduce or level cytokine activity, including in conditions characterized in whole or in part by angiogenesis and/or vessel leak.
    Type: Application
    Filed: May 27, 2022
    Publication date: September 15, 2022
    Inventors: Colin Richard GREEN, Odunayo Omolola Boluwarin MUGISHO, Bradford James DUFT
  • Publication number: 20220280473
    Abstract: The inventions relate to the use of anti-hemichannel compounds, including anti-connexin 43 hemichannel opening compounds, inhibitors and blockers, to modulate, suppress and stabilize epithelial-mesenchymal and/or endothelial-mesenchymal transition in diseases, disorders and conditions, including fibrotic diseases, disorders and conditions and other conditions associated with fibrosis.
    Type: Application
    Filed: March 2, 2022
    Publication date: September 8, 2022
    Inventors: Colin Richard GREEN, Odunayo Omolola Boluwarin MUGISHO, Brian LEVY
  • Patent number: 11427960
    Abstract: A process for bleaching trichome fibers individualized from a trichome source, such as a leaf and/or a stem, is disclosed. The process of bleaching degrades trichome associated protein. Further, the bleaching processes improves the color of the trichomes, exhibiting CIELAB Color values of L* greater than 87 and b* less than 17 and with less than 0.1% protein by weight of molecular weight greater than 3,500 daltons.
    Type: Grant
    Filed: June 26, 2019
    Date of Patent: August 30, 2022
    Assignee: The Procter & Gamble Company
    Inventors: Phillip Richard Green, Raul Victorino Nunes, Nicholas William Geary, Khosrow Parviz Mohammadi
  • Patent number: 11401516
    Abstract: The inventions relate to compositions and articles of manufacture comprising connexin modulators, pannexin modulators, gap junction modulators, hemichannel modulators, and pannexin channel modulators and their use, alone or in combination, in treating ocular and other disorders.
    Type: Grant
    Filed: November 4, 2019
    Date of Patent: August 2, 2022
    Assignees: AUCKLAND UNISERVICES LIMITED, OCUNEXUS THERAPEUTICS, INC.
    Inventors: Colin Richard Green, Yeri Kim, Anthony Phillips, Bradford James Duft
  • Patent number: 11390870
    Abstract: Methods and compositions for modulating the activities of connexins are provided, including, for example, for use in post-surgical, trauma, or tissue engineering applications. These compounds and methods can be used therapeutically, for example, to reduce the severity of adverse effects associated diseases and disorders where localized disruption in direct cell-cell communication is desirable.
    Type: Grant
    Filed: September 25, 2020
    Date of Patent: July 19, 2022
    Assignee: OCUNEXUS THERAPEUTICS, INC.
    Inventors: Wilda Laux, Colin Richard Green
  • Patent number: 11344603
    Abstract: The inventions relate to the use of hemichannel blockers to modulate cytokine levels in a subject, including the angiogenic cytokine, VEGF, and their production, secretion and/or release, and to the use of hemichannel blockers to reduce or level cytokine activity, including in conditions characterized in whole or in part by angiogenesis and/or vessel leak.
    Type: Grant
    Filed: July 19, 2018
    Date of Patent: May 31, 2022
    Assignees: AUCKLAND UNISERVICES LIMITED, OCUNEXUS THERAPEUTICS, INC.
    Inventors: Colin Richard Green, Odunayo Omolola Boluwarin Mugisho, Bradford James Duft
  • Publication number: 20210402104
    Abstract: An apparatus having an outer wall that encompasses an interior chamber that holds a predetermined volume of fluid and gas where the gas rises to one end of the interior chamber and the fluid flows to the other end of the interior chamber. The apparatus also has an inlet port that allows for fluid to ingress into the interior chamber and an outlet port that allows for fluid to egress out of the interior chamber.
    Type: Application
    Filed: September 14, 2021
    Publication date: December 30, 2021
    Inventors: Norton Herrick, David Saloff, Richard Green
  • Patent number: 11186589
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
    Type: Grant
    Filed: February 6, 2020
    Date of Patent: November 30, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Ian Stansfield, Olivier Alexis Georges Querolle, Yannick Aime Eddy Ligny, Gerhard Max Gross, Edgar Jacoby, Lieven Meerpoel, Simon Richard Green, George Hynd, Janusz Jozef Kulagowski, Calum Macleod, Samuel Edward Mann
  • Patent number: 11180487
    Abstract: The present invention relates to pharmaceutical agents of formula (I) useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: November 23, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Ian Stansfield, Olivier Alexis Georges Querolle, Virginie Sophie Poncelet, Gerhard Max Gross, Edgar Jacoby, Lieven Meerpoel, Janusz Jozef Kulagowski, Calum Macleod, Samuel Edward Mann, Simon Richard Green, George Hynd
  • Publication number: 20210310931
    Abstract: A contamination sensor for a gas turbine engine is disclosed herein. The contamination sensor is made of a selected composition of material and includes a base alloy, an alloy for improving oxide formation, and at least one element from the transition metal group. The composition of the contamination sensor can be adjusted to react with specific contaminants at specific temperature ranges.
    Type: Application
    Filed: April 6, 2020
    Publication date: October 7, 2021
    Applicant: Solar Turbines Incorporated
    Inventors: Noel Glaenzer, Richard Green, Prabhakar Mohan, Christopher Meyer
  • Patent number: 11136311
    Abstract: The present invention relates to pharmaceutical agents useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
    Type: Grant
    Filed: June 29, 2017
    Date of Patent: October 5, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Ian Stansfield, Olivier Alexis Georges Querolle, Yannick Aime Eddy Ligny, Gerhard Max Gross, Edgar Jacoby, Lieven Meerpoel, Simon Richard Green, George Hynd, Janusz Jozef Kulagowski, Calum Macleod, Samuel Edward Mann
  • Patent number: 11123497
    Abstract: An apparatus having an outer wall that encompasses an interior chamber that holds a predetermined volume of fluid and gas where the gas rises to one end of the interior chamber and the fluid flows to the other end of the interior chamber. The apparatus also has an inlet port that allows for fluid to ingress into the interior chamber and an outlet port that allows for fluid to egress out of the interior chamber.
    Type: Grant
    Filed: January 25, 2019
    Date of Patent: September 21, 2021
    Assignee: AILNH, LLC
    Inventors: Norton Herrick, David Saloff, Richard Green
  • Publication number: 20210222161
    Abstract: Provided are methods of producing nucleic acid libraries. The methods include combining single-stranded nucleic acid binding protein-bound single-stranded nucleic acid (SSB-bound ssNA), an adapter oligonucleotide, and a splint oligonucleotide, to form complexes including the splint oligonucleotide hybridized to a terminal region of the SSB-bound ssNA and to the adapter oligonucleotide. An end of the first adapter oligonucleotide is adjacent to an end of the first terminal region of the SSB-bound ssNA, and the methods may further include covalently linking the adjacent ends. Also provided are compositions and kits that find use, e.g., in practicing the methods of the present disclosure.
    Type: Application
    Filed: June 5, 2019
    Publication date: July 22, 2021
    Inventors: Richard Green, Joshua Kapp
  • Patent number: 11001569
    Abstract: The present invention relates to pharmaceutical agents of formula (I), useful for therapy and/or prophylaxis in a mammal, and in particular to inhibitors of NF-?B-inducing kinase (NIK—also known as MAP3K14) useful for treating diseases such as cancer, inflammatory disorders, metabolic disorders and autoimmune disorders. The invention is also directed to pharmaceutical compositions comprising such compounds, and to the use of such compounds or pharmaceutical compositions for the prevention or treatment of diseases such as a cancer, inflammatory disorders, metabolic disorders including obesity and diabetes, and autoimmune disorders.
    Type: Grant
    Filed: January 20, 2017
    Date of Patent: May 11, 2021
    Assignee: Janssen Pharmaceutica NV
    Inventors: Ian Stansfield, Olivier Alexis Georges Querolle, Gerhard Max Gross, Edgar Jacoby, Lieven Meerpoel, Janusz Jozef Kulagowski, Calum Macleod, Samuel Edward Mann, Simon Richard Green, George Hynd
  • Publication number: 20210115445
    Abstract: The inventions relate to compositions and articles of manufacture comprising connexin modulators, pannexin modulators, gap junction modulators, hemichannel modulators, and pannexin channel modulators and their use, alone or in combination, in treating ocular and other disorders.
    Type: Application
    Filed: December 11, 2020
    Publication date: April 22, 2021
    Inventors: Colin Richard GREEN, Yeri KIM, Anthony PHILLIPS, Bradford James DUFT
  • Patent number: D952348
    Type: Grant
    Filed: April 17, 2020
    Date of Patent: May 24, 2022
    Inventor: Richard Green
  • Patent number: D956961
    Type: Grant
    Filed: September 14, 2021
    Date of Patent: July 5, 2022
    Inventor: Richard Green